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Abstract 
Orexins are a class of neuropeptides that are associated with homeostatic functions, 
such as food intake, sexual behavior, and the sleep/wake cycle. Orexins also play a pivotal 
role in cognitive processes such as attention and memory. In the present experiment, we 
employed a visual attention task to assess the effects of intranasal administration of orexin 
A in rats. This task required the rats to discriminate between trials when a visual light was 
illuminated from trials when the light was not illuminated. We tested the efficacy of this 
administration technique to see its viability as a therapeutic in attention disorders. 
Intranasal orexin A decreased accuracy in the visual sustained attention task, specifically 
on trials when the light was not illuminated. This task performance decline may be due to 
the over-activation orexins, which in turn hyper-excites the acetylcholine-releasing 
neurons, a neurotransmitter system known to be critical for attention.    
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Introduction 
 Attention dysfunction is a symptom of a variety of diseases, including but not 
limited to, Autism (Allen & Courchesne, 2001), Attention Deficit Disorder (ADD) (Barkley et 
al, 1992), Alzheimer’s Disease (Perry et al, 2000), and Schizophrenia (Diwadkar et al, 
2014). Attentional dysfunction can have a significant negative impact in people’s lives, thus, 
treatments for these deficits are important. Attention is associated with the basal forebrain, 
hippocampus and parts of the thalamus (Posner & Petersen, 1990). With these regions of 
the brain being so important for different physiological functions it can be assumed that by 
changing the attention processing can also alter sensory processing and ultimately motor 
behaviors of the subject as well. The basal forebrain contains acetylcholine-releasing 
neurons, cells that are necessary for normal attentional processing. The hippocampus and 
thalamus are both used in memory formation and emotional processing; the thalamus is 
also the “relay” center, as all sensory information (besides olfaction) go through this 
structure (Posner & Petersen 1990). 
Alzheimer’s disease (AD) is a debilitating disease that more than 5 million people 
live with to date, and about 16 million people will be diagnosed with the disease by 2050 
(Alzheimer’s Association, 2017). AD is the sixth leading cause of death in America, and the 
onset of this disease typically occurs at 65 years of age and the prevalence increases in 
older groups (Alzheimer’s Association, 2017). AD is a neurodegenerative disease that is 
characterized, during early stages, by a decline in cognitive processing, especially attention 
and memory. As the disease progresses patients need more caregiving because of their 
diminishing ability to remember and complete daily activities. Thus, development of 
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therapeutics to help alleviate the symptoms are of high importance for patients and 
caregivers.  
Research demonstrates, in ADD and similar disorders there is frontal lobe hypo-
activity (Barkely et al, 1992). The frontal lobe is critical for normal executive functioning, 
such as selectively attending to environmental stimuli, inhibitory control (e.g. not doing 
something), working memory and cognitive flexibility. All of these different diseases that 
have attention problems have distinct causes and progress because of different 
mechanisms. However, enhancing the activity of the core neural circuitry underlying 
attention may have beneficial effects for multiple conditions characterized by aberrant 
attentional processing. 
 
Cholinergic System 
 Acetylcholine-releasing neurons located in the basal forebrain that project to the 
cortical regions of the brain, are essential for attention task performance (Sarter et al, 
2005). Research has shown cholinergic transmission in sensory areas (i.e. vision and 
audition) enhances the cortical processing of thalamic inputs (Sarter et al, 2005). Enhanced 
cortical processing is viewed as the ability to narrow the attention on the incoming stimuli 
while simultaneously filtering the irrelevant noise. This increased cortical processing helps 
with better controlled attention processing and working memory, potentially leading to 
more efficient long-term memory storage. The cholinergic system can also suppress the 
retrieval of internal cues (Sarter et al, 2005), which may distract an individual from target 
detection in the environment, therefore showing how this system is able to help focus the 
attention of the subject.  
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 Cholinergic inputs to the prefrontal cortex also mediate the filtering of irrelevant 
information (Sarter et al, 2005). Thus proper modulation of this system is important to be 
able to distinguish between different signals or cues.  
 
Orexins and Associated Receptors 
Neurotransmitters are usually at most a couple of amino acids in size. But orexins 
are in the class known as neuropeptides, which consist of more amino acids, with orexin A 
being comprised of 32 amino acids. Orexin A has two helices connected by a loop and then 
it has a hairpin-looped tail. Four cysteine residues create the two disulfide bridges that 
hold the hairpin structure in place. As this structure is very stable and has few charged 
residues it is able to bypass most lipid bilayers (Yin et al, 2015). This structure does not 
possess many large aromatic or large/bulky residues thus it is also able to pass through 
most cell membranes, making this neurotransmitter able to adapt to many different 
cellular environments.  
 Orexins have two receptors, orexin 1 receptor (OX1R) and orexin 2 receptor 
(OX2R). Both of these receptors engage GPCR signaling. Both have similar homologies, as 
they both are helix bundles that have a hydrophobic pocket (PubChem, 2018). The receptor 
will make contact with the hairpin loop of the orexin A ligand and start a GPCR mechanism 
cascade event. Orexin A has affinity for OX1R and OX2R, and Orexin B has affinity only for 
OX2R (Holmqvist et al, 2004). The specificity of these neurotransmitters makes it better for 
targeting specific receptors so that we know the direct effect of specific receptor activation. 
We wanted to look at the general effects of orexin administration. So, we picked orexin A, 
for we did not need to know specificity of the receptor action at this time. 
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Orexinergic System and Attention  
 The orexinergic system is shown to have significant influence on homeostasis by 
regulating processes such as, eating, drinking, sleep/wake cycle, and body temperature 
(Tang-Christensen et al, 1996). In addition, research has also demonstrated that orexin 
neurons can regulate attentional performance (Zajo et al, 2016).  Orexin receptor activation 
will subsequently stimulate a GPCR mechanism (Gs or Gi) to then activate adenylyl cyclase 
to create more cyclic AMP (cAMP). If more cAMP is produced then this will then activate 
both PKC (protein kinase C) and PLC (phospholipase C). The increase in these two proteins 
leads to two different cascades, but the end result for both is an increase of calcium, which 
will help with increasing conduction of the neuron. Increase in conduction of neurons has 
been shown to improve mental abilities and flexibility. Therefore orexins maybe used in a 
therapeutic sense to help increase neuronal firing to cholinergic cortical regions (Sarter et 
al, 2005). 
Orexins may be able to facilitate neural processing in other ways. For example, 
orexins may induce neuroplastic effects. These effects can increase of firing rate and 
potentially stimulate synaptogenesis. Increased synaptogenesis associated with increased 
connectivity, which can lead to more efficient biological systems (Bonci and Borgland, 
2009; Borgland et al, 2006) 
The ability of orexins to influence the cholinergic system has been well studied, but 
the best administration technique has not been concluded. Intravenous administration is 
limited by how easily drugs to cross the blood brain barrier or that neurosurgery can cause 
tissue damage. One viable low risk option would be to do intranasal administration 
(Thorne et al, 2004). The nasal passages are easily able to absorb most water and lipid 
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soluble drugs. The nasal pathway can be mapped to specific brain areas, being able to go to 
the cortices and as deep as the hippocampus and basal forebrain (Lochhead & Thorne, 
2013). Thus, intranasal administration potentially allows for a high concentration of 
orexins to be able to exert its effects on the cholinergic projections (Lochhead & Thorne, 
2013). 
 
Intranasal administration   
 Intranasal (IN) administration was previously thought to be an inferior way to 
administer drugs compared to intravenous (IV) or intraperitoneal (IP) administration. 
However, it has been shown that there was actually more Orexin A in the cerebral spinal 
fluid (CSF) of rats who got IN administration compared to IV administration (Lochhead et 
al, 2011). Thus, IN administration may be more useful for getting orexin A into the brain 
compared to IV administration.  
 In patients with varying diseases they need to be treated with an assortment of 
drugs, some taken orally, some taken via IP injection into the abdomen, and some have to 
be administered intravenously. Most of these methods have low absorption rates and are 
unable to get to their targets as easily. Because the nose is lined with a mucosa membrane 
on the inside it can easily have drugs that are lipophilic diffuse across it. Thus, using this as 
a drug transport seems like a reasonable alternative to other administration methods.  
Drugs can more easily pass through the nasal membrane with little disruption of 
tissue and can go directly to the brain. IV and IP injections disrupt tissue and other cell 
types while also being painful or even have detrimental impacts for the patient. Oral 
medications (e.g. pills or liquid medication) are not easily metabolized by the body, and 
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once they get to the target site they are not usually in the highest concentration (Lochhead 
J. & Thorne G., 2013). Also, if you want to raise the concentration of the drug pre-
administration you run into the problem of causing too much of the drug in the periphery, 
possibly leading to side effects. Thus using IN administration seems much more beneficial 
for its many advantages. Such advantages include, non-invasive/reduced infection rate, 
bigger surface area (approximately 160 cm2 for humans), rapid absorption (can bypass the 
blood brain barrier), and the drugs avoid elimination through first-pass metabolism in the 
hepatic system.  
There are of course some drawbacks of IN administration, such as the active 
mucociliary clearance, low pH of the nasal passage, and you must use smaller volumes of 
the drugs (Lochhead J. & Thorne G., 2013). Mucociliary clearance describes the cilia of the 
respiratory tract expelling incoming foreign substances; low pH can denature or change the 
conformations of drugs. Lastly, the nasal passage can only uptake so much liquid at once, 
limiting the volume of a particular drug.  
 
Neuroinflammation    
 Neuroinflammation is the activity of pro-inflammatory factors, which will then 
cause cells to take up more water and become “inflamed.” This activation has negative 
consequences because inflammation decreases neural plasticity, which can impact a variety 
of processes, including cognition (Lynch, 2015). Neuroinflammation will also cause 
microglial activation, due to the fact that inflammation in time will cause the neurons to 
undergo apoptosis (Duffy et al, 2015). Microglia can be beneficial for removing cellular 
debris, but constant activation can be deleterious. Microglia have reactive oxygen species 
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(ROS) as byproducts, which will cause further disruption of cells leading to more 
inflammation, which in turn will cause more activation of these microglia (Duffy et al, 
2015).   
 Activation of orexin receptors can down-regulate microglia, which helps lessen the 
neuroinflammation (Duffy, 2015). With less neuroinflammation there will be less reactive 
oxygen species and cellular debris can hinder the firing rate. Allowing firing rates to speed 
up will lead to an improvement of cognition. Without excitotoxic effects, the neurons 
should be properly functioning to then help them fire faster which subsequently will allow 
for better attention scores.  
 Neuroinflammation can be activated by different factors, such as internal pro-
inflammatory factors or exterior insults, such as surgery or brain trauma. A study 
conducted in 2007 proved that neurosurgery will increase interleukin 1beta (IL-1β) RNA in 
rats post surgery. IL-1β is a pro-inflammatory factor that has been shown to decrease 
neuron viability, which leads to apoptosis (Roscyzk, 2008). The same study also took a 
survey showing that the elderly who got neurosurgery have more cognitive deficits post 
surgery.  
 
Measuring Attention in Animal Models 
 There are several different methods for measuring attention. Depending on what 
type of attention one wishes to study different tasks are used. There is sustained, spatial, 
divided, and alternating attention (Yantis & Johnston, 1990). The Morris Water Maze is 
used to help asses spatial attention as the rats are trying to locate a submerged platform be 
able to stay above water. This test helps understand how rodents navigate a tank with 
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minimal cues to be able to find the platform (Svensson et al, 2017). Researchers can use a 
Simultaneity Test DIAT-SHIF to be able to measure the ability of the subject to shift 
between two different stimuli (CogniFit, 2018). An example of an alternating attention task 
is cooking a meal, as you read the recipe and cooks the meal.   
In this study we measured the sustained attention of rats. We are able to measure 
attention by using operant box conditioning to quantify the rats’ responses. Once the rat 
gets into the box there are two extended levers, which the rat will have to identify as the 
correct response. The goal of this experiment is to test whether orexin A changes the 
accuracy of responding in this attention task.  
 
The Present Experiment   
The goal of the experiment was to test the effects of IN orexin A administration on 
attentional performance. There are two possible outcomes for the experiment. First, orexin 
A could enhance attention, consistent with a previous finding with intracranial orexin A 
infusions. An alternative possibility is that activation of the orexin receptors via this 
administration method will lead to hyper-excitation. If there is too much saturation of the 
orexin receptors we will see the over-excitatory inputs to the cholinergic system, which 
will cause deficits in attentional performance.  
 
 Material and Methods 
Subjects 
 12 male FBNF1 hybrid rats (National Institute of Aging Colony), weighing 320 grams 
to 490 grams, at 3 months old starting at the beginning of the study. The rats were housed 
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in pairs in a temperature and humidity-controlled vivarium, with a 12hr light/dark cycle. 
All behavioral testing and drug administration occurred during the light phase. All rats 
were water restricted throughout the experiment, only receiving water as a reward in the 
attention task and then, 30 minutes after the test session, rats were given ad libitum tap 
water access for 10 minutes. The rats were tested 6-7 days a week, and on non-testing days 
they would receive 20 minutes of water access. Food was available ad libitum throughout 
the study. All procedures were approved by the Animal Care and Use Committee at the 
College of William and Mary.    
 
Apparatus 
 Rats were trained in one of four chambers, each located within a sound-attenuating 
box (Med. Associates, Inc.). Each chamber included a water dipper that could be raised to 
afford access to tap (0.01mL). Two levers were located on either side of the dipper. A panel 
light was above each lever and another light was above the dipper. A house light was on the 
opposite side of the chamber from the dipper and panel lights. Illumination levels of these 
chambers have been measured and described (Burk, 2004). Behavioral testing programs 
and data collection was monitored on a personal computer using Med-PC version IV 
software. 
 
Attention Task Procedure 
 Testing took place between 9:00am to 4:00pm daily. Rats were trained initially to 
press an extended lever using a fixed ratio-1 (FR-1) schedule of reinforcement. Rats moved 
to the next phase of training once they received 120 rewards per session for three sessions. 
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In the second stage of training, there were two trial types, a signal trial and a non-signal 
trial. On a signal trial the center panel light would illuminate (1 second) and on a non-signal 
trial the light was not illuminated. A press on one lever was considered correct on signal 
trials and a press on the other lever was considered correct on non-signal trials. If the rats 
pressed the correct lever for a trial they receive water access for 3 seconds via the water 
dipper. The left lever was considered correct on signal trials for half of the animals and the 
right lever was considered correct on non-signal trials half of the rats and the rules were 
reversed for the other half of the rats. Each session lasted for about 45 minutes. The inter-
trial interval (ITI) was 12 seconds. Once the rats reached at least a 70% accuracy on signal 
and non-signal for three consecutive days with a maximum of 60 omissions (failure to 
press either lever) they would move to the final stage. Before drug infusions began they 
moved into the last stage of training. In this task the signal duration varied between 500 
ms, 100 ms, or 25 ms, and the ITI (9±3 seconds) was shorter and varied to create more 
attention demand (Zajo et al, 2016). Each training session consists of 162 trials (81 signal 
trials and 81 non-signal trials). For signal trials each of the three signal durations were 
presented for 27 trials within a session. Each trial was present in blocks of 18 (9 non-signal 
and 9 signal with 3 of each signal duration), and trial types were selected at random 
without replacement. Once reaching >70% success on all trial types then they move onto 
drug infusions and distracter test.     
 
Drug Administration and Behavioral Testing Sessions 
 Orexin A was prepared a day before the first drug administration session and kept 
in the freezer until drug administration began. Mixing 500 µg of Orexin A (Tocris) with 
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140.4 mL of saline solution for a final concentration of 1000 nM. Then a second dilution 
was performed, taking 1mL of stock solution and mixing 9 mL of saline for a final 
concentration of 100nM. Before drug infusion days the rats were acclimated to the 
intranasal administration technique by infusing saline 3 days a week for two weeks. A 
volume of 0.25 µL of saline into each rats’ nostril by placing a pipette immediately near the 
nostril entry and administering the drug. Then the rats were intranasally administered 
0.25 µL of orexin A (High dose= 1000 nM; Low dose= 100nM; Vehicle= Saline) 
approximately five minutes before they were put through their attention test. Rats received 
a total of three infusion sessions, receiving each drug dose once, in an order that was 
randomly assigned for each rats. On drug administration days the rats performed a 
“distracter” version of the task. The distracter version of the task was the same as pre-drug 
administration training, except that the houselight in the back of the chamber was flashed 
(1 second on/1 second off) during the second block of trials (trials 55-108) during the 
testing session. The first and third trial blocks were the same (no houselight flashing) as 
during pre-drug administration training  
  
Behavioral Measures and Statistical Analysis  
 The number of hits (H), misses (M), correct rejections (CR), false alarms (FA), and 
omissions were recorded for each animal on every testing day. The relative hits were 
calculated as such: [H/(H+M)]; relative correct rejections were calculated as such: 
[FA/(FA+CR)]. During the drug infusion days, the baseline version of the test, where the 
houselight is continuously illuminated, occurred for the first 54 trials (block 1). Then for 
the next 54 trials (block 2), the houselight was flashed as a distracter. The houselight was 
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continuously illuminated for the final 54 trials in a testing session (block 3). Omissions 
were calculated separately from measures of accuracy. The hit rate, correct rejection rate, 
and omissions were determined for each block of trials in the testing session. 
 Repeated-measures Analyses of Variance (ANOVAs) were conducted. The factors in 
each analysis included drug dose (saline, 100mM, 1000mM) and block (block 1, block 2 
when the distracter was presented, and block 3). For analyses of hits, signal duration (500, 
100, 25 ms) were included. Significant main effects and interactions were assessed with 
follow-up t-tests or additional ANOVAs to clarify the basis of the significant effects. An 
alpha level of .05 was used to determine statistical significance. 
 
Results  
 For hits, a dose X block X signal duration ANOVA yielded significant main effect of 
block interactions  (F(2,22)=9.614,p=0.001).  Subsequent t-test indicated that the hit rate 
was higher in block one compared to block three (t(11)=4.607,p=0.001). Hits were also 
higher during block two compared to block three although this result was not significant 
when the Bonferroni correction was applied.  
Correct rejections (CR) reflect accuracy on non-signal trials. A dose X block ANOVA 
was conducted to assess effects of orexin A administration on CR. There was a significant 
dose X block interaction  (F(2,22)=7.291,p=0.004). .Follow-up one-way ANOVAs including 
the factor block for each dose (vehicle, low dose, high dose) yielded a significant effect of 
block when the low dose was administered (F(2,22)=7.721, p=.003), but not when vehicle 
or the high dose were administered. Subsequent paired t test shows that, for the low dose, 
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accuracy is higher during block 1 compared to block 3 (t(11)=4.737,p=0.001), and that 
correct rejections are higher during block 2 compared to block 3 (t(11)=2.617,p=0.024). 
An omission is when a rat does not press any lever when both of the choice levers 
are extended. A dose X block ANOVA did not yield a main effect or interaction involving 
dose, indicating that drug treatment did not differentially affect the rats’ response rate. 
 
Discussion 
 The results suggest that IN administration effectively activates orexin receptors, but 
that the doses in the present experiment were sufficiently high to impair attentional 
performance. We did not see significant effects for the doses on the hits (see figure 1); we 
saw a general trend of worsening scores, but no dose difference. This might be because 
there is a saturation effect with the activation of the orexin receptors. The same amount of 
receptors might be activated in both doses, thus the doses should be adjusted accordingly. 
One possibility is that orexin A was able to be easily absorbed so we saw declines in task 
performance due to over-activation of orexin receptors. We tested this method of 
administration with orexin so that we can observe the impact that the high molarity of 
orexins have on direct administration via intranasal injections. The nasal cavity is made of 
a mucosa membrane, which allows entry to the brain immediately after administration. 
Labs have shown that following an IN injection of orexin A leads to a 5 to 8 fold increase in 
concentration of orexin A in the brain compared to IV injections (Dhuria et al, 2009). We 
see that the attention scores of the rats are severely impacted by the orexin A 
administration sessions compared to the vehicle (saline).  
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 We see that, in a measure of visual attention, accuracy on non-signal trials decreases 
following orexin A administration compared to the vehicle (saline).  One potential reason 
for this effect is that orexin neurons were over excited, which has shown to significantly 
decrease the accuracy of the attention performance of the rats. Previous research has 
shown that cholinergic system hyper-excitation leads to decreases in accuracy on non-
signal trials in the present attention task (Sarter, M., & Bruno, J., 2004).  
 For the correct rejections, orexin A does not produce significant differences in 
accuracy compared with vehicle administration during the first block of trials within a 
testing session. The rats also displayed similar scores for the second block as well. 
However, during the third block, when the rats were recovering from the distracter, the 
low dose rats showed a sharp deficit going into their last block compared to the vehicle rats 
(see figure 2). The vehicle-treated rats were able to recover from the distracter, as their 
performance is similar on the first and third block of the trials in the attention task. The 
most interesting result from this experiment was the effect of the low orexin A dose on the 
rats’ correct rejections. The rats at the low dose actually displayed higher hit percentages 
in the first block than the other two dose groups. They also did better on block 2, but when 
it came to block 3 they did very poorly. This might have to do for the fact that orexins are 
helping the rats at first with this low dose or producing a bias to press the hit/false alarm 
lever. Once orexin A is in their system long enough and attentional demands are altered via 
distraction, we see a sharp decline in their accuracy. Their omissions get higher as well; 
thus showing a corollary effect of how the orexins being metabolized can affect their 
attention (see figure 3).  
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Future Directions 
 This experiment suggests that IN orexin A administration can affect cognition. 
Several different future directions arise from these results. First, histological 
experimentation to explore the cellular receptor system of the basal forebrain and 
hippocampus regions with regard to orexin receptor activity needs to be examined. For 
example, staining for orexin 1 receptors and acetylcholine receptors to see if there is 
correlation in the synaptic densities of the varying dose groups. This staining has been 
done in other studies prior (Fadel et al, 2001), but in this study we would be looking at the 
impact of intranasal administration. We would be specifically looking at if there were any 
up or down regulations of orexin receptors or acetylcholine receptors. This will help 
further our understanding of how the activation of the orexin receptor can impact neural 
plasticity of the cholinergic and orexinergic systems.   
 Many drugs are known to impair attentional performance and effect Ach 
functioning. For example, cannabinoids are a specialized endogenous neurotransmitter as 
well as an exogenous molecule found in plants and synthetic compounds. Just like orexins 
they can impact for attention and homeostatic activity (Huang et al, 2007). But unlike 
orexins, cannabinoids are shown to only be detrimental for attention and memory. From 
this experiment we then want to take this new information about the ability of intranasal 
administration and apply it to another system of interest. For example, it would be 
interesting to test whether cannabinoid receptor agonist-induced attentional impairments 
can be reversed by IN orexin A (Ramírez et al, 2005). IN orexin A administration may be 
able to normalize depressed cholinergic functioning induced by cannabinoid receptor 
agonists (Crespo et al, 2009). This treatment plan would be beneficial for people who have 
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underactive orexin systems (such as people who are habitual cannabis users or people who 
have developed AD). In contrary, this treatment plan would not be good for people who 
have overexcited Ach-releasing neurons, for it would over activate it too much and lead to 
cognitive difficulties.    
 With the largest growing demographic in the country being the elderly, and tending 
toward cognitive challenges and underactive cholinergic system, it becomes imperative to 
develop treatments to facilitate cognitive processing. If we can attenuate age-related 
cognitive decline or improve the symptoms in pathological conditions, such as AD in a 
timely fashion, then we are able to cut out a lot of taxpayers’ dollars. Financials aside, these 
less invasive treatment options are very beneficial not only for the elderly but for the whole 
population.  
 In closing, orexin A may be useful to normalize low acetylcholine levels. This 
experiment shows the efficacy of intranasal administration and how to use this method so 
that we can have better and more efficient drug administration treatments.        
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Figures: 
 
 
 
 
 
 
 
Figure 1 Hits 
 
No significant differences with the doses of orexin on the hits, but there is a declining 
trend in the hits with the orexin doses. 
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Figure 2 Correct Rejections  
 
There are significant deficits transitioning from the 2nd block to the 3rd block for 
the low dose. The higher dose shows a similar trend, but is not significant. Lastly, 
the vehicle there is a recovery of CR after the 2nd block. 
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Figure 3 Omissions  
 
There are no significant changes on omissions, but there is a trend of more 
omissions with both of the orexin doses. 
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